FDA accepts NDA and grants priority review of Zuranolone from Sage Therapeutics, Biogen EP News Bureau Feb 7, 2023 Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder…
